STING1 and colorectal cancer: This hypothesis is in agreement with a previous study showing that the anticancer activity of i.v. applied liposomal oxaliplatin formulations in colorectal cancer-bearing mouse models was significantly enhanced by intratumoral administration of the STING agonist ADU-S100.51 This suggests that achieving sufficiently high intratumoral concentrations of the STING agonist is critical for optimal synergistic anticancer effects.